Recent studies have demonstrated RORα reprograms glucose metabolism in glutamine-deficient hepatoma cells, but also inhibits aerobic glycolysis activity in hepatoma cells treated with the RORα activator SR1078 by reducing the expression of pyruvate dehydrogenase kinase 2 (PDK2), inhibiting the phosphorylation of pyruvate dehydrogenase and shifting pyruvate to complete oxidation [12]. This evidence concerns the gene PDK2 and hepatocellular carcinoma.